Quarterly ResultAug 13, 2026, 04:26 PM
PDS Biotech Q2 Net Loss $9.75M; Negative Equity, Going Concern
AI Summary
PDS Biotechnology reported a net loss of $(9.75) million for the second quarter of 2026, with stockholders' equity turning negative to $(3.58) million. The company's cash and cash equivalents significantly declined to $5.60 million, and management expressed substantial doubt about its ability to continue as a going concern. Additionally, PDS Biotechnology discontinued its Phase 3 trial for PDS0101 and repaid $22.2 million in debt, while also establishing a new $50 million ATM program.
Key Highlights
- Stockholders' equity turned negative to $(3.58) million as of June 30, 2026, from $9.25 million at December 31, 2025.
- Cash and cash equivalents decreased to $5.60 million as of June 30, 2026, from $26.71 million at December 31, 2025.
- Reported a net loss of $(9.75) million for the three months ended June 30, 2026, compared to $(9.43) million for the same period in 2025.
- Discontinued its Phase 3 trial with PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer in August 2026.
- Management concluded substantial doubt exists about the company's ability to continue as a going concern.
- Repaid $22.2 million in senior secured convertible debentures on June 15, 2026.
- Net cash used in operating activities decreased to $(7.16) million for the six months ended June 30, 2026, from $(18.13) million in 2025.
- Entered a new At-The-Market (ATM) program in June 2026 for up to $50 million in common stock sales.
Price Impact
More from PDSB